Investor Presentaiton
The prevalence of anaemia increases as CKD progresses; it is associated with
an increased risk of hospitalisation, cardiovascular complications and death
gsk
North America
30 million
CKD prevalence
Europe
25 million
CKD prevalence
16 million
Stages 3-5
19 million
Treating patients with anaemia due to CKD
Stages 3-5
Diagnosed
Average
treatment
Stage of
CKD
Kidney
function %
patients
duration
(m)
(years)
Primary care
physician
and
Nephrologist
Stage 3a
45-59
4.4
7.9
Stage 3b
30-44
5.6
5.0
Stage 4
15-29
1.3
4.2
Asia
Nephrologist
Stage 5
<15%
0.5
0.8
367 million
CKD prevalence
123 million
Stages 3-5
Source: 1. NHANES 2016 data accessed via Centers for Disease Control and Prevention. CKD Surveillance System-United States; website: http://www.cdc.gov/ckd; 2. 2018 USRDS Annual data report-Volume 2: ESRD in the US 3. Lancet: Global, regional and national
burden of chronic kidney disease, 1990-2017; 4. The prevalence of Chronic Kidney Disease in Asia, Liyanage T, Toyama T, ISN WCN 2020. 5 Spherix RealWorld Dynamix ND Patient Audit Neph and PCP-2019, 6: GSK internal materials, 7. Dowling TC. Am J Health Syst
Pharm 2007;64(13 Suppl 8):S3-7., Schmidt RJ, Dalton CL. Osteopath Med Prim Care 2007;1:14.
21View entire presentation